Skip to main content
OpenTrials

Clinical trial condition

Hypersensitivity

Explore clinical trials studying Hypersensitivity. Study availability and eligibility vary by location and protocol.

6,740 public trials 644 recruiting studies
Refine in advanced search Browse all conditions

Hypersensitivity trial results

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 205.418.01020 Boehringer Ingelheim Investigational Site Huntington Beach, California, United States
  • 205.418.01002 Boehringer Ingelheim Investigational Site Mission Viejo, California, United States
  • 205.418.01014 Boehringer Ingelheim Investigational Site San Diego, California, United States
  • 205.418.01011 Boehringer Ingelheim Investigational Site Wheat Ridge, Colorado, United States
View all 114 locations
View Trial Details
Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

NCT01108848

Conditions
Angioedema, Angioedemas, Hereditary, Cardiovascular Diseases, +14 more
Locations
  • United States, Arizona Scottsdale, Arizona, United States
  • United States, California Granada Hills, California, United States
  • United States, California Los Angeles, California, United States
  • United States, California Redding, California, United States
View all 40 locations
View Trial Details
Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 205.419.01058 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 205.419.01053 Boehringer Ingelheim Investigational Site Stockton, California, United States
  • 205.419.01061 Boehringer Ingelheim Investigational Site Centennial, Colorado, United States
  • 205.419.01066 Boehringer Ingelheim Investigational Site Denver, Colorado, United States
View all 125 locations
View Trial Details
Completed

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

NCT00317044

Conditions
Asthma, Bronchial Diseases, Deglutition Disorders, +13 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Scottsdale, Arizona, United States
  • Research Site Little Rock, Arkansas, United States
  • Research Site Fountain Valley, California, United States
View all 130 locations
View Trial Details
Completed

Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma

NCT00849095

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • Ospedale regionale Umberto I, Unità Operativa di Allergologia Ancona, AN, Italy
  • Fondazione S. Maugeri - IRCCS -dipartimento di Pneumologia riabilitativa Cassano delle Murge, BA, Italy
  • Dipartimento di Scienze Mediche-Unità Operativa di Pneumologia Benevento, BN, Italy
  • Policlinico Sant'Orsola Malpighi, Unità Operativa di Pneumologia Bologna, BO, Italy
View all 31 locations
View Trial Details
Completed

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01826461

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +10 more
Locations
  • UCSD - Rady Children's Hospital San Diego, California, United States
  • Northwestern University Chicago, Illinois, United States
  • Sneeze, Wheeze & Itch Associates, LLC Normal, Illinois, United States
  • Minnesota Clinical Study Center Fridley, Minnesota, United States
View Trial Details

Related conditions